IONS Form 4: O'Neil Executes Option Exercise and 10b5-1 Sale of 1,700 Shares
Rhea-AI Filing Summary
Patrick R. O'Neil, Executive Vice President, Chief Legal Officer and General Counsel of Ionis Pharmaceuticals (IONS), reported option exercise and an offsetting sale on 09/12/2025. He exercised a non-qualified stock option to purchase 1,700 shares at a $56.78 exercise price and concurrently sold 1,700 shares under a Rule 10b5-1 trading plan for a weighted average price of $64.5807, leaving him with 55,503 shares directly owned and 57,130 shares following the transactions as reported. The filing includes an explanation that the shares sold were transacted at prices ranging from $64.53 to $64.605 and that the sale was pursuant to a 10b5-1 plan adopted May 2, 2025.
Positive
- Transaction disclosed promptly on Form 4 with signature and explanation
- Sale executed under a Rule 10b5-1 plan, indicating pre-arranged trading and reduced risk of opportunistic timing
- Commitment to provide trade-level pricing details on request enhances transparency
Negative
- Reduction in direct beneficial ownership by 1,700 shares following the sale
- Insider monetized shares, which may be viewed unfavorably by some investors despite being planned
Insights
TL;DR: Routine insider option exercise and programmed sale under a 10b5-1 plan, disclosed and signed.
The report shows a standard exercise of a non-qualified stock option and an immediate sale executed under a pre-established Rule 10b5-1 plan. The disclosure includes the weighted average sale price range and a commitment to provide detailed trade-level pricing on request, which aligns with good governance and SEC reporting practices. The transactions did not change control and appear administrative rather than strategic.
TL;DR: Insider monetized gain from option exercise via planned sales; impact on ownership is modest.
The exercise price of $56.78 and weighted average sale price of $64.5807 imply a realized gross gain per share before taxes and fees. The net effect reduced reported direct holdings modestly from 58,830 to 57,130 shares following the transactions. Because the sale was pre-planned under a 10b5-1 agreement and the sizes are small relative to total outstanding shares, this is unlikely to be material to company valuation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 1,700 | $0.00 | -- |
| Exercise | Common Stock | 1,700 | $56.78 | $97K |
| Sale | Common Stock | 1,700 | $64.5807 | $110K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.53 to $64.605 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
